Masamichi Sugimoto

发表

Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

K. Hagihara, Jian Song, T. Kishimoto, 2003, Arthritis and rheumatism.

Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model

T. Iwai, S. Harada, Masamichi Sugimoto, 2016, Oncology reports.

Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.

Y. Ohsugi, Y. Matsumoto, M. Okazaki, 2005, International immunopharmacology.

Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model

R. Nakamura, O. Kondoh, M. Monnai, 2019, Clinical & Experimental Metastasis.

Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non-small Cell Lung Cancer Xenograft Models.

Nobuyuki Ishikura, T. Iwai, Masamichi Sugimoto, 2017, Anticancer research.

Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The essential role of macrophages

Masamichi Sugimoto, Takahiro Ishiguro, Masami Suzuki, 2009 .

Human Liver Cancer Glypican 3 Antibody as a Potential Antitumor Agent for − Anti

H. Aburatani, T. Kodama, M. Tsuchiya, 2008 .

Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1low and immune desert-like mouse tumors

Nobuyuki Ishikura, O. Kondoh, Masamichi Sugimoto, 2021, Oncology reports.

Effect of Bevacizumab on a Human Breast Cancer Model that Exhibited Palbociclib-resistance by RB Knockout.

Nobuyuki Ishikura, O. Kondoh, D. Wakita, 2022, Cancer diagnosis & prognosis.

Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes

H. Ogino, Y. Nishioka, Atsuro Saijo, 2021, The Journal of Immunology.

Optimization of tissue processing for immunohistochemistry for the detection of human glypican-3.

H. Kataoka, Masamichi Sugimoto, Takahiro Ishiguro, 2010, Acta histochemica.

Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.

H. Aburatani, T. Kodama, M. Tsuchiya, 2009, Biochemical and biophysical research communications.

2D7 diabody bound to the alpha2 domain of HLA class I efficiently induces caspase-independent cell death against malignant and activated lymphoid cells.

M. Tsuchiya, Y. Hirata, Toshio Matsumoto, 2004, Biochemical and biophysical research communications.

Human interleukin‐6 induces human herpesvirus‐8 replication in a body cavity‐based lymphoma cell line

R. Inagi, Jian Song, K. Yamanishi, 2002, Journal of medical virology.

Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.

H. Aburatani, T. Kodama, M. Tsuchiya, 2008, Cancer research.

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model

Nobuyuki Ishikura, K. Furugaki, T. Iwai, 2017, International journal of oncology.

Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade

Miho Suzuki, T. Iwai, S. Harada, 2019, AntiCancer Research.

Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization

M. Tsuchiya, T. Igawa, H. Tsunoda, 2010, Anti-cancer drugs.

Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab

D. Shames, Miho Suzuki, N. Patil, 2021, Scientific Reports.

Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression

Y. Yatabe, M. Aoki, S. Nagahashi, 2014, Molecular Cancer Therapeutics.

Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies

T. Iwai, D. Wakita, Masamichi Sugimoto, 2018, Oncotarget.

PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8+ T cells in hematogenous metastasis model with lymphocyte infusion

O. Kondoh, D. Wakita, Masamichi Sugimoto, 2021, Clinical & Experimental Metastasis.

Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade.

H. Ogino, Y. Nishioka, M. Hanibuchi, 2023, Cell reports.

Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model

R. Nakamura, O. Kondoh, M. Monnai, 2019, Clinical & Experimental Metastasis.

A defucosylated anti‐CD317 antibody exhibited enhanced antibody‐dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients

Toshio Matsumoto, S. Ozaki, K. Habu, 2010, Cancer science.

Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The contribution of macrophages.

Masamichi Sugimoto, Takahiro Ishiguro, Masami Suzuki, 2009, Cancer biology & therapy.

Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model

Nobuyuki Ishikura, Masamichi Sugimoto, K. Yorozu, 2019, Oncology reports.

Anti-VEGF Antibody Protects against Alveolar Exudate Leakage Caused by Vascular Hyperpermeability, Resulting in Mitigation of Pneumonitis Induced by Immunotherapy

O. Kondoh, T. Iwai, Masamichi Sugimoto, 2021, Molecular Cancer Therapeutics.

PD-L1 and VEGF dual blockade enhances anti-tumor effect on brain metastasis in hematogenous metastasis model.

Masamichi Sugimoto, K. Yorozu, M. Kurasawa, 2024, Clinical & experimental metastasis.